Novel extended in vitro-in vivo correlation model for the development of extended-release formulations for baclofen: From formulation composition to in vivo pharmacokinetics

被引:14
|
作者
Kim, Tae Hwan [1 ]
Bulitta, Jurgen B. [2 ]
Kim, Do-Hyung [3 ]
Shin, Soyoung [4 ]
Shin, Beom Soo [5 ]
机构
[1] Daegu Catholic Univ, Coll Pharm, Gyongsan 38430, Gyeongbuk, South Korea
[2] Univ Florida, Coll Pharm, Orlando, FL 32827 USA
[3] KNOTUS Co Ltd, Res Ctr, Guri 11910, Gyeonggi, South Korea
[4] Wonkwang Univ, Coll Pharm, 460 Iksan Daero, Iksan 54538, Jeonbuk, South Korea
[5] Sungkyunkwan Univ, Sch Pharm, Suwon, Gyeonggi, South Korea
基金
新加坡国家研究基金会;
关键词
Extended-release formulation; In vitro-in vivo correlation; Population pharmacokinetic model; Hydroxypropyl methylcellulose; Baclofen; INTESTINAL-ABSORPTION; POPULATION; TRANSPORT; MECHANISM; TABLETS; DESIGN; TIME;
D O I
10.1016/j.ijpharm.2018.12.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In vitro-in vivo correlation (IVIVC), a predictive mathematical model between the in vitro dissolution and the in vivo pharmacokinetics has been utilized for the development of new extended release (ER) formulations. The aim of the present study was to extend the IVIVC approach, which correlates among the formulation composition, the in vitro dissolution, and the plasma drug concentration, to predict plasma drug concentrations from a given composition of the formulation, and vice versa, using baclofen as a model drug. Baclofen ER tablets with different dissolution rates were prepared by varying the composition of hydroxypropyl methylcellulose (HPMC). First, the HPMC compositions and the corresponding in vitro dissolutions parameters were correlated, and then the in vitro dissolution parameters were correlated with the in vivo dissolution parameters extracted from the pharmacokinetic profiles of the baclofen ER formulations via population pharmacokinetic modeling. The final extended IVIVC model linked the composition of the formulation, the in vitro dissolution, and the in vivo plasma concentration profile and was successfully applied for the prediction of in vivo pharmacokinetics from the amount of HPMC in baclofen ER formulations. The present approach holds great promise for designing optimal compositions of ER formulations to present desired plasma concentration profile.
引用
收藏
页码:276 / 286
页数:11
相关论文
共 50 条
  • [1] Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
    Mohamed, Mohamed-Eslam F.
    Trueman, Sheryl
    Othman, Ahmed A.
    Han, Jian-Hwa
    Ju, Tzuchi R.
    Marroum, Patrick
    AAPS JOURNAL, 2019, 21 (06):
  • [2] Development of an Extended-Release Formulation of Capecitabine Making Use of In Vitro-In Vivo Correlation Modelling
    Meulenaar, Jelte
    Keizer, Ron J.
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Huitema, Alwin D. R.
    Nuijen, Bastiaan
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (02) : 478 - 484
  • [3] Development and validation of an in vitro-in vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations
    Cheng, Chinhwa
    Wu, Pao-Chu
    Lee, Hsin-Ya
    Hsu, Kuang-Yang
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2014, 22 (02) : 257 - 263
  • [4] Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro-in Vivo Correlation Study in Beagle Dogs
    Tang, Meiqiong
    Hu, Ping
    Huang, Shigui
    Zheng, Qiang
    Yu, Hao
    He, Yun
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2016, 64 (11) : 1607 - 1615
  • [5] Development of In Vitro–In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation
    Mohamed-Eslam F. Mohamed
    Sheryl Trueman
    Ahmed A. Othman
    Jian-Hwa Han
    Tzuchi R. Ju
    Patrick Marroum
    The AAPS Journal, 21
  • [6] In Vitro/In Vivo Correlation of Two Extended-Release Cilostazol Formulations
    Min, Kyoung Ah
    Kim, Na Young
    Jin, Min Jeong
    Kim, Doyeon
    Ma, Yoonseo
    Karna, Sandeep
    Park, Young-Joon
    PHARMACEUTICALS, 2024, 17 (06)
  • [7] Evaluation of "external" predictability of an in vitro-in vivo correlation for an extended-release formulation containing metoprolol tartrate
    Mahayni, H
    Rekhi, GS
    Uppoor, RS
    Marroum, P
    Hussain, AS
    Augsburger, LL
    Eddington, ND
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 89 (10) : 1354 - 1361
  • [8] Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability
    Kakhi, Maziar
    Marroum, Patrick
    Chittenden, Jason
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (05) : 262 - 277
  • [9] Development of an In Vitro Drug Release Method to Enable In Vitro-In Vivo Correlation of Potassium Chloride Extended-Release Tablets
    Qiu, Yihong
    Zhu, Donghua Alan
    Apfelbaum, Kathleen
    Zu, Hui
    Xiong, Hao
    MOLECULAR PHARMACEUTICS, 2022, 19 (11) : 4191 - 4198
  • [10] Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation
    Kim, Tae Hwan
    Shin, Soyoung
    Bulitta, Jurgen B.
    Youn, Yu Seok
    Yoo, Sun Dong
    Shin, Beom Soo
    MOLECULAR PHARMACEUTICS, 2017, 14 (01) : 53 - 65